Cancer Chemotherapy and Pharmacology

, Volume 71, Issue 3, pp 825–828 | Cite as

Immunohistochemical study of MRP5 expression in meningiomas

  • George A. Alexiou
  • Ann Goussia
  • Antigoni Ntoulia
  • Panagiota Zagorianakou
  • Vasiliki Malamou-Mitsi
  • Spyridon Voulgaris
  • Athanasios P. Kyritsis
Short Communication



Meningiomas are the most common benign intracranial tumor, accounting for 30 % of all primary intracranial tumors. Although benign meningiomas rarely recur after a complete resection, anaplastic tumors are associated with high recurrence rate and unfavorable outcome. In the current study, we investigated the expression of the multidrug resistance protein 5 (MRP5) in patients with meningiomas.


We retrospectively studied twenty patients with meningiomas that were treated surgically in our institute over a 3-year period. MRP5 protein expression was determined immunohistochemically.


The immunohistochemical expression of MRP5 was observed only in anaplastic meningiomas. No MRP5 expression was detected in benign or atypical meningiomas. No significant correlation was found between MRP5 expression and Ki-67 index. After a mean follow-up period of 23 months, there were 4 cases of tumor recurrence. No correlation was found between extent of resection and tumor recurrence.


Immunohistochemical MRP5 protein expression was observed only in anaplastic meningiomas. Further research is needed to clarify whether MRP5 is indicative of malignant pathological features in meningiomas and whether possible therapeutic implications exist.


MRP5 Meningioma Ki-67 Recurrence 


Conflict of interest



  1. 1.
    Alexiou GA, Gogou P, Markoula S et al (2010) Management of meningiomas. Clin Neurol Neurosurg 112:177–182PubMedCrossRefGoogle Scholar
  2. 2.
    Sioka C, Kyritsis AP (2009) Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 92:1–6PubMedCrossRefGoogle Scholar
  3. 3.
    Tews DS, Nissen A, Kulgen C et al (2000) Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 50:227–237PubMedCrossRefGoogle Scholar
  4. 4.
    Berger W, Spiegl-Kreinecker S, Buchroithner J et al (2001) Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 94:377–382PubMedCrossRefGoogle Scholar
  5. 5.
    Haroun RI, Clatterbuck RE, Gibbons MC et al (2002) Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. J Neurooncol 58:115–123PubMedCrossRefGoogle Scholar
  6. 6.
    Spiegl-Kreinecker S, Buchroithner J, Elbling L et al (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 57:27–36PubMedCrossRefGoogle Scholar
  7. 7.
    Tews DS, Fleissner C, Tiziani B et al (2001) Intrinsic expression of drug resistance-associated factors in meningiomas. Appl Immunohistochem Mol Morphol 9:242–249PubMedCrossRefGoogle Scholar
  8. 8.
    Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, Moumdjian R, Berthelet F, Béliveau R et al (2001) Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer 93:62–66PubMedCrossRefGoogle Scholar
  9. 9.
    Kunishio K, Kobayashi K, Kagawa M, Makabe T, Matsumoto A, Matsumoto Y (2007) A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene. Gan To Kagaku Ryoho 34:265–268PubMedGoogle Scholar
  10. 10.
    Alexiou GA, Goussia A, Voulgaris S et al (2012) Prognostic significance of MRP5 immunohistochemical expression in glioblastoma. Cancer Chemother Pharmacol 69:1387–1391PubMedCrossRefGoogle Scholar
  11. 11.
    Allen KE, Weiss GJ (2010) Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9:3126–3136PubMedCrossRefGoogle Scholar
  12. 12.
    Demeule M, Régina A, Jodoin J et al (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharmacol 38:339–348CrossRefGoogle Scholar
  13. 13.
    Bronger H, Konig J, Kopplow K et al (2005) ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood tumor barrier. Cancer Res 65:11419–11428PubMedCrossRefGoogle Scholar
  14. 14.
    Chamberlain MC (2004) Intracerebral meningiomas. Curr Treat Options Neurol 6:297–305PubMedCrossRefGoogle Scholar
  15. 15.
    Stewart DJ, Dahrouge S, Wee M et al (1995) Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J Neurooncol 24:189–194PubMedCrossRefGoogle Scholar
  16. 16.
    Dallas S, Miller DS, Bendayan R (2006) Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev 58:140–161PubMedCrossRefGoogle Scholar
  17. 17.
    Kuan CT, Wakiya K, Herndon JE II et al (2010) MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 10:468PubMedCrossRefGoogle Scholar
  18. 18.
    Kaufmann AM, Toro-Ramos AJ, Krise JP (2008) Assessment of golgi apparatus versus plasma membrane-localized multi-drug resistance-associated protein 1. Mol Pharm 5:787–794PubMedCrossRefGoogle Scholar
  19. 19.
    Scheffer GL, Kool M, Heijn M et al (2000) Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60:5269–5277PubMedGoogle Scholar
  20. 20.
    Kuan CT, Srivastava N, McLendon RE et al (2010) Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 127:598–611PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • George A. Alexiou
    • 1
  • Ann Goussia
    • 2
  • Antigoni Ntoulia
    • 2
  • Panagiota Zagorianakou
    • 1
  • Vasiliki Malamou-Mitsi
    • 2
  • Spyridon Voulgaris
    • 1
  • Athanasios P. Kyritsis
    • 3
  1. 1.Department of NeurosurgeryUniversity Hospital of IoanninaIoanninaGreece
  2. 2.Department of PathologyUniversity Hospital of IoanninaIoanninaGreece
  3. 3.Department of Neurology, Neurosurgical InstituteUniversity Hospital of IoanninaIoanninaGreece

Personalised recommendations